{"id":75009,"date":"2026-08-17T15:26:02","date_gmt":"2026-08-17T07:26:02","guid":{"rendered":"https:\/\/flcube.com\/?p=75009"},"modified":"2026-08-17T15:26:03","modified_gmt":"2026-08-17T07:26:03","slug":"astrazeneca-launches-tezspire-in-china-bringing-first-in-class-tslp-inhibitor-tezepelumab-to-severe-asthma-and-crswnp-patients","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75009","title":{"rendered":"AstraZeneca Launches Tezspire in China, Bringing First\u2011In\u2011Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients"},"content":{"rendered":"\n

AstraZeneca plc<\/strong> (NYSE: AZN<\/a>) announced the official market launch in China of Tezspire<\/strong> (generic name: tezepelumab injection<\/strong>). The commercialization milestone brings China’s patients the first\u2011in\u2011class TSLP inhibitor<\/strong> for severe asthma and chronic rhinosinusitis with nasal polyps, following Chinese regulatory approval in March 2026.<\/p>\n\n\n\n

Launch Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>AstraZeneca plc (NYSE: AZN)<\/td><\/tr>
Product<\/strong><\/td>Tezspire (tezepelumab injection)<\/td><\/tr>
Milestone<\/strong><\/td>Official market launch in China<\/td><\/tr>
China Approval<\/strong><\/td>March 2026, based on Phase III DIRECTION and WAYPOINT trials<\/td><\/tr>
Co\u2011Developer<\/strong><\/td>Amgen<\/td><\/tr>
Announcement Date<\/strong><\/td>17 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Approved Indications in China<\/h2>\n\n\n\n
Indication<\/th>Population & Setting<\/th><\/tr><\/thead>
Severe Asthma<\/strong><\/td>Maintenance treatment for adults and adolescents aged 12 and older<\/strong><\/td><\/tr>
CRSwNP<\/strong><\/td>In combination with intranasal corticosteroids for adults with chronic rhinosinusitis with nasal polyps<\/strong> inadequately controlled by systemic corticosteroids and\/or surgery<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n